Flotufolastat F-18

Short description: Medication

Flotufolastat F-18

Flotufolastat F-18 gallium

Clinical data
Trade names| Posluma
Other names| 18F-rhPSMA-7.3
License data|

* US DailyMed: f-18 Flotufolastat f-18

Routes of
administration| Intravenous
ATC code|

* None

Legal status
Legal status|

* US: ℞-only [1]

Identifiers
CAS Number|

* 2639294-14-5

PubChem CID|

* 166177191

DrugBank|

* DB17851

UNII|

* 811W19E3OL
* XD423NK2WO

KEGG|

* D12606

Chemical and physical data
3D model (JSmol)|

* Interactive image
* Interactive image

SMILES

* CC(C)(C)[Si]([18F])(C1=CC=C(C=C1)C(=O)NC[C@@H](NC(=O)CC[C@H](N1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1)C(O)=O)C(=O)N[C@H](CCCCNC(=O)CCC(=O)NCCC[C@@H](NC(=O)CC[C@H](NC(=O)N[C@@H](CCC(O)=O)C(O)=O)C(O)=O)C(O)=O)C(O)=O)C(C)(C)C

CC(C)(C)[Si](C1=CC=C(C=C1)C(=O)NC[C@H](C(=O)N[C@H](CCCCNC(=O)CCC(=O)NCCC[C@H](C(=O)O)NC(=O)CC[C@@H](C(=O)O)NC(=O)N[C@@H](CCC(=O)O)C(=O)O)C(=O)O)NC(=O)CC[C@@H](C(=O)O)N2CCN(CCN(CCN(CC2)CC(=O)[O-])CC(=O)[O-])CC(=O)[O-])(C(C)(C)C)[18F].[Ga+3]

InChI

* InChI=1S/C63H99FN12O25Si/c1-62(2,3)102(64,63(4,5)6)39-14-12-38(13-15-39)54(89)67-34-44(69-49(80)20-18-45(60(99)100)76-32-30-74(36-52(85)86)28-26-73(35-51(83)84)27-29-75(31-33-76)37-53(87)88)55(90)70-41(57(93)94)10-7-8-24-65-46(77)21-22-47(78)66-25-9-11-40(56(91)92)68-48(79)19-16-42(58(95)96)71-61(101)72-43(59(97)98)17-23-50(81)82/h12-15,40-45H,7-11,16-37H2,1-6H3,(H,65,77)(H,66,78)(H,67,89)(H,68,79)(H,69,80)(H,70,90)(H,81,82)(H,83,84)(H,85,86)(H,87,88)(H,91,92)(H,93,94)(H,95,96)(H,97,98)(H,99,100)(H2,71,72,101)/t40-,41-,42+,43+,44-,45+/m1/s1/i64-1

* Key:QMGJNAVROCDAIW-MQNQVPOESA-N

InChI=1S/C63H99FN12O25Si.Ga/c1-62(2,3)102(64,63(4,5)6)39-14-12-38(13-15-39)54(89)67-34-44(69-49(80)20-18-45(60(99)100)76-32-30-74(36-52(85)86)28-26-73(35-51(83)84)27-29-75(31-33-76)37-53(87)88)55(90)70-41(57(93)94)10-7-8-24-65-46(77)21-22-47(78)66-25-9-11-40(56(91)92)68-48(79)19-16-42(58(95)96)71-61(101)72-43(59(97)98)17-23-50(81)82;/h12-15,40-45H,7-11,16-37H2,1-6H3,(H,65,77)(H,66,78)(H,67,89)(H,68,79)(H,69,80)(H,70,90)(H,81,82)(H,83,84)(H,85,86)(H,87,88)(H,91,92)(H,93,94)(H,95,96)(H,97,98)(H,99,100)(H2,71,72,101);/q;+3/p-3/t40-,41-,42+,43+,44-,45+;/m1./s1/i64-1;

* Key:OJPQWJNFDOFXTN-WRFPGERRSA-K

Flotufolastat F-18, sold under the brand name Posluma, is a radioactive diagnostic agent for use with positron emission tomography (PET) imaging for prostate cancer.[1] The active ingredient is flotufolastat F-18 gallium.[1]

Flotufolastat F-18 was approved for medical use in the United States in May 2023.[1][2]

## Medical uses

Flotufolastat F-18 is indicated for positron emission tomography of prostate-specific membrane antigen positive lesions in men with prostate cancer.[1][3]

## References

1. ↑ 1.0 1.1 1.2 1.3 1.4 "Posluma- flotufolastat f-18 injection". 2 June 2023. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=907ac4a4-a088-4826-ab50-cfc31985c9d4.
2. ↑ "U.S. FDA Approves Blue Earth Diagnostics' Posluma (Flotufolastat F 18) Injection, First Radiohybrid PSMA-targeted PET Imaging Agent for Prostate Cancer" (Press release). Blue Earth Therapeutics. 30 May 2023. Retrieved 25 June 2023 - via Business Wire.
3. ↑ "Flotufolastat F 18: Diagnostic First Approval". Molecular Diagnosis & Therapy 27 (5): 631–636. September 2023. doi:10.1007/s40291-023-00665-y. PMID 37439946. https://figshare.com/articles/online_resource/Flotufolastat_F_18_Diagnostic_First_Approval/23631417.

## External links

* Clinical trial number NCT04186819 for "Imaging Study to Investigate the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) in Newly Diagnosed Prostate Cancer (LIGHTHOUSE)" at ClinicalTrials.gov
* Clinical trial number NCT04186845 for "Imaging Study to Investigate Safety and Diagnostic Performance of rhPSMA 7.3 (18F) PET Ligand in Suspected Prostate Cancer Recurrence (SPOTLIGHT)" at ClinicalTrials.gov

* v
* t
* e

Diagnostic radiopharmaceuticals (ATC: V09)

Central nervous system|

* 99mTc (Exametazime)
* 123I (Ioflupane
* Iofetamine
* Iomazenil)
* 18F (Florbetapir, Flutemetamol)

Skeletal system|

* 99mTc (Medronic acid)

Renal|

* 123I (Sodium iodohippurate)
* 64Cu (Cu-ETS2)

Gastrointestinal/Hepatic|

* 75Se (SeHCAT)

Respiratory system|

* 133Xe
* 81mKr
* 99mTc (99mTc-MAA)

Cardiovascular system|

* 99mTc (Sestamibi
* Tetrofosmin)
* 111In (Imciromab)
* 82Rb (Rubidium chloride)

Inflammation/infection|

* 99mTc (Exametazime
* Sulesomab
* Tilmanocept)
* 111In
* 67Ga

Tumor|

* 99mTc (Arcitumomab
* Votumumab
* Hynic-octreotide)
* 111In (Capromab pendetide
* Satumomab pendetide)
* 125I (Minretumomab)
* 123I / 131I (Iobenguane)
* 18F (Fluciclovine
* Fludeoxyglucose
* Fluoroethyltyrosine
* Sodium fluoride)

Adrenal cortex|

* 123I
* 125I / 131I (Iodocholesterol)

Radionuclides
(including tracers)|

| positron (PET list)|

* 11C ([11C]ME@HAPTHI
* 25B-NBOMe (Cimbi-36)
* Acetate
* Choline
* Carfentanil
* DASB
* DTBZ
* Flumazenil
* Methionine
* N-Methylspiperone
* Pittsburgh compound B
* Raclopride
* Verapamil)
* 13N (Ammonia)
* 15O (Water)
* 18F (Altanserin
* Desmethoxyfallypride
* FMISO
* Fallypride
* Florbetaben
* Florbetapir
* Flubatine
* Fluciclovine
* Fludeoxyglucose (18F) (FDG)-glucose analogue
* Flumazenil
* Fluorocholine
* Fluorodeoxysorbitol (FDS)
* Fluorodopa
* Fluorothymidine F-18
* Fluspidine
* Flutemetamol
* MPPF
* Mefway
* Nifene
* N-Methylspiperone
* FET
* Setoperone)
* 64Cu
* 68Ga
* 82Rb (Rubidium chloride)

|

gamma ray/photon (SPECT/scintigraphy)|

* 51Cr
* 57Co
* 67Ga
* 75Se
* 81mKr
* 99mTc
* 111In
* 123I
* 125I
* 131I
* 133Xe
* 153Sm
* 201Tl

0.00

(0 votes)

|

Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:Flotufolastat_F-18&oldid=3869854"
*[US]: United States
*[CID]: Compound ID
*[v]: View this template
*[t]: Discuss this template
*[e]: Edit this template